653 related articles for article (PubMed ID: 16836561)
21. Removal of virus through novel membrane filtration method.
Manabe S
Dev Biol Stand; 1996; 88():81-90. PubMed ID: 9119166
[TBL] [Abstract][Full Text] [Related]
22. Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step.
Koenderman AH; ter Hart HG; Prins-de Nijs IM; Bloem J; Stoffers S; Kempers A; Derksen GJ; Al B; Dekker L; Over J
Biologicals; 2012 Nov; 40(6):473-81. PubMed ID: 22901944
[TBL] [Abstract][Full Text] [Related]
23. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
24. Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles.
Adan-Kubo J; Tsujikawa M; Takahashi K; Hongo-Hirasaki T; Sakai K
Biotechnol Prog; 2019 Nov; 35(6):e2875. PubMed ID: 31228338
[TBL] [Abstract][Full Text] [Related]
25. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
26. A proficiency testing study to evaluate laboratory performance for the detection of different genotypes of parvovirus B19.
Baylis SA; Buchheit KH
Vox Sang; 2009 Jul; 97(1):13-20. PubMed ID: 19416495
[TBL] [Abstract][Full Text] [Related]
27. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of viral removal by nanofiltration using real-time quantitative polymerase chain reaction.
Zhao X; Bailey MR; Emery WR; Lambooy PK; Chen D
Biotechnol Appl Biochem; 2007 Jun; 47(Pt 2):97-104. PubMed ID: 17233631
[TBL] [Abstract][Full Text] [Related]
29. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
[TBL] [Abstract][Full Text] [Related]
30. Pathogen safety of Beriate®.
Gröner A
Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
[TBL] [Abstract][Full Text] [Related]
31. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
[TBL] [Abstract][Full Text] [Related]
32. Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives.
Berting A; Goerner W; Spruth M; Kistner O; Kreil TR
J Med Virol; 2005 Apr; 75(4):603-7. PubMed ID: 15714487
[TBL] [Abstract][Full Text] [Related]
33. Inactivation and neutralization of parvovirus B19 Genotype 3.
Blümel J; Rinckel LA; Lee DC; Roth NJ; Baylis SA
Transfusion; 2012 Jul; 52(7):1490-7. PubMed ID: 22339291
[TBL] [Abstract][Full Text] [Related]
34. Effect of antibody solution conditions on filter performance for virus removal filter Planova 20N.
Hongo-Hirasaki T; Komuro M; Ide S
Biotechnol Prog; 2010; 26(4):1080-7. PubMed ID: 20730765
[TBL] [Abstract][Full Text] [Related]
35. Validation of new real-time polymerase chain reaction assays for detection of hepatitis A virus RNA and parvovirus B19 DNA.
Molenaar-de Backer MW; de Waal M; Sjerps MC; Koppelman MH
Transfusion; 2016 Feb; 56(2):440-8. PubMed ID: 26354230
[TBL] [Abstract][Full Text] [Related]
36. Blood protein purification and simultaneous removal of nonenveloped viruses using tangential-flow preparative electrophoresis.
Evtushenko M; Wang K; Stokes HW; Nair H
Electrophoresis; 2005 Jan; 26(1):28-34. PubMed ID: 15624167
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa.
Compston LI; Li C; Sarkodie F; Owusu-Ofori S; Opare-Sem O; Allain JP
J Med Virol; 2009 Nov; 81(11):1860-8. PubMed ID: 19774687
[TBL] [Abstract][Full Text] [Related]
38. Discovery and analysis of a novel parvovirus B19 Genotype 3 isolate in the United States.
Rinckel LA; Buno BR; Gierman TM; Lee DC
Transfusion; 2009 Jul; 49(7):1488-92. PubMed ID: 19389024
[TBL] [Abstract][Full Text] [Related]
39. Parvovirus B19 genotypes 1 and 2 detection with real-time polymerase chain reaction assays.
Koppelman MH; Rood IG; Fryer JF; Baylis SA; Cuypers HT
Vox Sang; 2007 Oct; 93(3):208-15. PubMed ID: 17845257
[TBL] [Abstract][Full Text] [Related]
40. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products.
Unger U; Poelsler G; Modrof J; Kreil TR
Transfusion; 2009 Sep; 49(9):1924-30. PubMed ID: 19453977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
